Eva U. Graefe-Mody

629 total citations
12 papers, 547 citations indexed

About

Eva U. Graefe-Mody is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Eva U. Graefe-Mody has authored 12 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Oncology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Eva U. Graefe-Mody's work include Diabetes Treatment and Management (7 papers), Peptidase Inhibition and Analysis (6 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Eva U. Graefe-Mody is often cited by papers focused on Diabetes Treatment and Management (7 papers), Peptidase Inhibition and Analysis (6 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Eva U. Graefe-Mody collaborates with scholars based in Germany, Austria and Japan. Eva U. Graefe-Mody's co-authors include Klaus A. Dugi, Arne Ring, Tim Heise, Dirk Trommeshauser, Atsushi Taniguchi, Hans‐Juergen Woerle, Yoshiharu Horie, Akiko Sarashina, Steven J. Padula and Naoyuki Hayashi and has published in prestigious journals such as Blood, Clinical Pharmacology & Therapeutics and Journal of Thrombosis and Haemostasis.

In The Last Decade

Eva U. Graefe-Mody

12 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva U. Graefe-Mody Germany	11	484	260	172	153	138	12	547
Ulrike Graefe‐Mody Germany	15	760 1.6×	291 1.1×	303 1.8×	319 2.1×	131 0.9×	19	861
Elizabeth Bandeira-Echtler Germany	4	345 0.7×	68 0.3×	116 0.7×	156 1.0×	31 0.2×	5	409
Masashi Hirayama Japan	9	352 0.7×	107 0.4×	164 1.0×	193 1.3×	32 0.2×	19	443
Fabrizio Querci Italy	12	525 1.1×	57 0.2×	182 1.1×	255 1.7×	37 0.3×	20	615
R. Teng United States	7	384 0.8×	74 0.3×	151 0.9×	178 1.2×	14 0.1×	7	412
Ivano Franzetti Italy	14	430 0.9×	42 0.2×	177 1.0×	212 1.4×	31 0.2×	21	604
Xiaozhou Yao United States	8	57 0.1×	188 0.7×	116 0.7×	165 1.1×	31 0.2×	12	382
Bernice Ellis United States	7	313 0.6×	24 0.1×	158 0.9×	233 1.5×	45 0.3×	10	434
Judi A. McNulty United States	9	129 0.3×	134 0.5×	118 0.7×	159 1.0×	8 0.1×	9	390
Fred Yang United States	9	771 1.6×	33 0.1×	300 1.7×	386 2.5×	30 0.2×	17	867

Countries citing papers authored by Eva U. Graefe-Mody

Since Specialization

Citations

This map shows the geographic impact of Eva U. Graefe-Mody's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva U. Graefe-Mody with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva U. Graefe-Mody more than expected).

Fields of papers citing papers by Eva U. Graefe-Mody

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva U. Graefe-Mody. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva U. Graefe-Mody. The network helps show where Eva U. Graefe-Mody may publish in the future.

Co-authorship network of co-authors of Eva U. Graefe-Mody

This figure shows the co-authorship network connecting the top 25 collaborators of Eva U. Graefe-Mody. A scholar is included among the top collaborators of Eva U. Graefe-Mody based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva U. Graefe-Mody. Eva U. Graefe-Mody is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Friedrich, Christian, et al.. (2011). Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics. 36(1). 17–24. 35 indexed citations

Horie, Yoshiharu, Shigeto Kanada, Hirotaka Watada, et al.. (2011). Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients. Clinical Therapeutics. 33(7). 973–989. 42 indexed citations

Graefe-Mody, Eva U., et al.. (2011). Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 49(5). 300–310. 16 indexed citations

Ring, Arne, et al.. (2011). The DPP‐4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. British Journal of Clinical Pharmacology. 72(1). 39–50. 26 indexed citations

Sarashina, Akiko, Shogo Sesoko, Mitsuyoshi Nakashima, et al.. (2010). Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects. Clinical Therapeutics. 32(6). 1188–1204. 53 indexed citations

Graefe-Mody, Eva U., Arvid Jungnik, Arne Ring, Hans J. Woerle, & Klaus A. Dugi. (2010). Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 48(10). 652–661. 25 indexed citations

Heise, Tim, et al.. (2009). Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients. Diabetes Obesity and Metabolism. 11(8). 786–794. 155 indexed citations

Graefe-Mody, Eva U., et al.. (2009). Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Current Medical Research and Opinion. 25(8). 1963–1972. 53 indexed citations

Graefe-Mody, Eva U., et al.. (2008). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers. The Journal of Clinical Pharmacology. 48(10). 1171–1178. 116 indexed citations

10.

Leitner, Judith, Bernd Jilma, Florian Mayr, et al.. (2007). Pharmacokinetics and Pharmacodynamics of the Dual FII/FX Inhibitor BIBT 986 in Endotoxin-induced Coagulation. Clinical Pharmacology & Therapeutics. 81(6). 858–866. 14 indexed citations

11.

Graefe-Mody, Eva U., et al.. (2006). Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. Journal of Thrombosis and Haemostasis. 4(7). 1502–1509. 10 indexed citations

12.

Jilma, Bernd, Judith Leitner, Francesco Cardona, et al.. (2006). The Effect of BIBT 986, a Novel Small Molecule Dual Inhibitor of Thrombin and Factor Xa, on Coagulation in a Model of Endotoxin Induced, Tissue Factor Triggered Coagulation Activation in Humans.. Blood. 108(11). 912–912. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact